1. **Keiichiro Watanabe, Masahiro Abe, Cui Qu, Makoto Kawatani, Masahiro Hiasa, Ayako Nakano, Tadashi Jinno, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Hiroyuki Osada, Eiji Tanaka *and* Toshio Matsumoto :** The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma, Travel Grant Award, 2010., 10th International Conference Cancer-Induced Bone Disease, Sep. 2010.
2. **Keiichiro Watanabe, Masahiro Abe, Qu Cui, Makoto Kawatani, Masahiro Hiasa, Ayako Nakano, Tadashi Jinno, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Hiroyuki Osada *and* Toshio Matsumoto :** An acidic milieu created in myeloma-osteoclast interaction enhances tumor growth, but triggers anti-myeloma activity of Reveromycin A, a novel anti-resorptive agent, 52nd ASH Travel Award, 52nd ASH, Dec. 2010.
3. **Masahiro Hiasa, A Nakano, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, H Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki *and* Toshio Matsumoto :** Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression, IOF-ANZBMS Travel Award., Japanese Association for Dental Research, Jul. 2011.
4. **日浅 雅博, A Nakano, 渡邉 佳一郎, C Qu, T Harada, 藤井 志朗, H Miki, 中村 信元, 賀川 久美子, 竹内 恭子, 田中 栄二, 淺岡 憲三, 尾崎 修治, 松本 俊夫 :** Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition., 4. Hiasa M, Nakano A, Watanabe K, Qu C, Harada T, Fujii S, Miki H, Nakamura S, Kagawa K, Takeuchi K, Tanaka E, Asaoka K, Ozaki S, Matsumoto T, Abe M:, 米国骨代謝学会, 2011年9月.
5. **Keiichiro Watanabe, Masahiro Abe, H Mori, R Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka *and* Toshio Matsumoto :** 5. Potent induction of bone formation in myeloma bone lesions by the cathepsin K inhibitor KK1-300-01 in combinat ion with the proteasome inhibitor bortezomib., Plenary poster & Young Investigator Travel Award, The American Society for Bone and Mineral Research, Oct. 2013.
6. **天眞 寛文, 寺町 順平, 小田 明日香, 天知 良太, 日浅 雅博, 渡邉 佳一郎, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :** 破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される, 第34回日本骨代謝学会学術集会・第3回アジア太平洋骨代謝学会議,Young investigator award., 日本骨代謝学会, 2016年7月.
7. **Hirofumi Tenshin, Jumpei Teramachi, A Oda, Ryota Amachi, Masahiro Hiasa, A Baterdene, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto *and* Masahiro Abe :** Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts., ANZBMS Plenary Poster Award., Australian and New Zealand Bone and Mineral Society, Jun. 2017.
8. **日浅 雅博, 寺町 順平, 天眞 寛文, 谷本 幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸郎, 田中 栄二, 松本 俊夫, 安倍 正博 :** カテプシンK阻害による多発性骨髄腫骨病変部の骨量回復プロセスにおける骨細胞の役割, 第36回日本骨代謝学会学術集会 研究奨励賞., 日本骨代謝学会, 2019年7月.